Oramed Pharmaceuticals Inc. ORMP
4.13 USD +0.13 (+3.25%)
At closeNov 4, 2026, 6:44 PM EST
4.11 -0.02 -0.54%
After hours · Nov 4, 6:44 PM ET
4.05 Day range 4.14
2.09 52-week range 5.47
- YTD
- +44.91%
- 1 year
- +81.14%
- Market cap
- 169.02M
- EPS (ttm)
- 4.25
- Shares out
- 40.31M
- P/E ratio
- 0.97
- Forward P/E
- -29.75
- YTD return
- +44.91%
- 1-year return
- +81.14%
- Volume
- 119.67K
- Avg volume
- 176.61K
- Open
- 4.05
- Previous close
- 4.00
- Day's range
- 4.05 – 4.14
- 52-week range
- 2.09 – 5.47
- Beta
- 1.77
- Price target
- 3.25 (-21.3%)
2Y +1.69 (+70.71%)
Key statistics
- Enterprise value
- -47.25M
- PEG ratio
- 0.00
- Price / book
- 0.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -2.41M
- Total cash
- 142.30M
- Total debt
- 429.00K
- Return on equity
- 2.89%
- Short % of float
- 0.82%
- 50-day average
- 2.38
- 200-day average
- 2.43
Analyst view
Price target (mean) 3.25
Ratings (0m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.07.
Financials — quick view
ORMP Revenue — quarterly 0
ORMP Net income — quarterly 78.16M
ORMP EPS — quarterly 1.90
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.01 | -0.48 | -0.49 | -4,900.00% |
| Aug 14, 2024 | Jun 1, 2024 | 0.01 | 0.22 | +0.21 | +2,100.00% |
| May 9, 2024 | Mar 1, 2024 | 0.02 | 0.04 | +0.02 | +100.00% |
| Mar 6, 2024 | Dec 1, 2023 | -0.12 | -0.08 | +0.04 | +33.33% |
| Nov 9, 2023 | Sep 1, 2023 | -0.09 | -0.08 | +0.01 | +11.11% |
| Aug 10, 2023 | Jun 1, 2023 | -0.11 | -0.03 | +0.08 | +72.73% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| May 20, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| May 17, 2023 | Canaccord Genuity | main | Hold | Hold |
| Jan 17, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Jan 12, 2023 | Canaccord Genuity | down | Buy | Hold |
| May 16, 2022 | Aegis Capital | main | — | Buy |
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- oramed.com
News
Contrasting Recursion Pharmaceuticals (NASDAQ:RXRX) & Oramed Pharmaceuticals (NASDAQ:ORMP) 
Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) and Generate Biomedicines (NASDAQ:GENB) 
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More 
12 Health Care Stocks Moving In Thursday's Intraday Session 
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet 
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet 
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes 
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction 
Reviewing Oramed Pharmaceuticals (NASDAQ:ORMP) & Akanda (NASDAQ:AKAN) 
Lifeward Closes The Strategic Partnership Agreement With Oramed Pharmaceuticals
Your note
Sign in to keep a note on ORMP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGHION DANIEL | Director | Stock Award(Grant) | Jan 29, 2024 | 38,820 |
| GABAY AVRAHAM | Chief Financial Officer | Stock Award(Grant) | Nov 6, 2024 | 170,040 |
| HEXTER JOSHUA | Chairman of the Board | Stock Award(Grant) | Nov 6, 2024 | 511,833 |
| KIDRON MIRIAM | Officer | Stock Award(Grant) | Nov 6, 2024 | 793,666 |
| KIDRON NADAV | Chief Executive Officer | Stock Award(Grant) | Nov 6, 2024 | 1,952,100 |
| MAYER ARIE PH.D. | Director | Stock Award(Grant) | Jan 3, 2024 | 96,134 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BML Capital Management, LLC | 5.42% | 2,186,191 | 5.20M | Sep 29, 2024 |
| Murchinson Ltd. | 4.24% | 1,708,879 | 4.07M | Sep 29, 2024 |
| Boothbay Fund Management, LLC | 2.05% | 828,331 | 1.97M | Sep 29, 2024 |
| Rathbones Group PLC | 0.72% | 289,803 | 689.73K | Sep 29, 2024 |
| Two Sigma Advisers, LP | 0.63% | 255,600 | 608.33K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.61% | 245,300 | 583.81K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Micro Cap ETF | 0.21% | 84,637 | 201.44K | Oct 30, 2024 |
| SPDR Portfolio Developed World ex-US ETF | 0.12% | 47,512 | 113.08K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 25,455 | 60.58K | Oct 30, 2024 |
| Avantis U.S. Small Cap Equity ETF | 0.04% | 15,439 | 36.74K | Sep 29, 2024 |
| SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF | 0.03% | 12,544 | 29.85K | Sep 29, 2024 |
| DFA U.S. Targeted Value Portfolio | 0.02% | 7,512 | 17.88K | Jul 30, 2024 |